EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy

Dongyuan Wang, Yajing Liu, Ying Chen, Chuan Dai, Wenzhu Hu, Jinyan Han, Zigang Li, Feng Yin, Yu Zhang, Chen Shi iD

Advanced Science · 2025

DOI: 10.1002/advs.202510197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Dongyuan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Aniline Compounds, Acrylamides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osimertinib resistance is a global problem for NSCLC patients mediated by new EGFR mutations or bypass mechanisms. Proteolysis targeting chimeras (PROTACs) have been utilized to overcome drug resistance by degrading mutant EGFR, but most are restricted to their poor cell permeability and insufficient tumor‐targeting ability. Meanwhile, these PROTACs has little effect on bypass resistance mechanisms. In this study, a versatile split‐and‐mix liposomal PROTAC is developed for EGFR degradation based on liposome self‐assembly containing DSPE‐PEG2000‐E3 ligand and DSPE‐PEG2000‐EGFR ligand. Unlike traditional PROTACs, this platform can achieve efficient EGFR degradation via both E3‐dependent mechanisms and the lysosome‐autophagy pathway. To further increase its sensitivity to osimertinib‐resistant lung cancer cells, the liposomal PROTAC is encapsulated with class I HDAC inhibitor MS‐275 (GM‐protac) by both blocking the EGFR‐dependent pathways and bypass resistant mechanisms. GM‐protac shows selective toxicity on gefitinib‐resistant and osimertinib‐resistant lung cancer cells. The mechanism analysis reveals that GM‐protac can influence the BIM‐associated apoptosis pathway, c‐Met, PD‐L1, HER‐2, NF‐κB or PI3K‐AKT signaling pathway, etc. Meanwhile, they displayed obvious tumor inhibition with negligible toxicity in both osimertinib and gefitinib‐resistant lung cancer animal models. This work provides an alternative option for osimertinib‐resistant lung cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrug Resistance, NeoplasmAniline CompoundsAcrylamidesEpigenesis, GeneticCarcinoma, Non-Small-Cell LungHumansErbB ReceptorsAnimalsMiceLiposomesCell Line, TumorProteolysisAntineoplastic AgentsMice, NudeIndolesPyrimidines

Stichwörter der Autor:innen

HDACepigenetic regulationliposomal PROTAClung cancerosimertinib resistance

Substanzen

osimertinibErbB ReceptorsAniline CompoundsAcrylamidesLiposomesEGFR protein, humanAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, China.
  • State Key Laboratory of Chemical Oncogenomic, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.
  • Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518118, China.
  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

ORCID-Profile: Chen Shi

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, D., Liu, Y., Chen, Y., Dai, C., Hu, W., Han, J., Li, Z., Yin, F., Zhang, Y., & Shi, C. (2025). EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy. Advanced Science. https://doi.org/10.1002/advs.202510197

Vancouver

Wang D, Liu Y, Chen Y, Dai C, Hu W, Han J, et al. EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy. Advanced Science. 2025. doi:10.1002/advs.202510197

BibTeX
@article{Wang2025,
  author = {Wang, Dongyuan and Liu, Yajing and Chen, Ying and Dai, Chuan and Hu, Wenzhu and Han, Jinyan and Li, Zigang and Yin, Feng and Zhang, Yu and Shi, Chen},
  title = {EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202510197}
}
Kostenlos starten →